Proteocyte’s Chief Scientific Officer, Dr. Ranju Ralhan, was invited to participate in the first ever Global Oral Cancer Forum to present a poster: Early Detection of Oral Lesions with Dysplasia at High Risk of Cancer Development Using A Proteomic Signature Image Analysis Based Straticyte™. The Straticyte™ poster presentation generated a lot of interest amongst the attendees, won a “Best Poster Award” and placed third overall in the poster competition.
Proteocyte Diagnostics provides a laboratory service, Straticyte™, for early identification of oral lesions likely to progress to cancer. Late detection of oral cancer is widely acknowledged as the primary reason for the 50% mortality rate for this disease, so early detection is critical.
“Based on the data presented at the poster presentation, Straticyte™ has great potential in identifying high risk, oral potentially malignant disorders by differentiating low risk from high risk lesions. In the past, we have treated this group of OPMDs without distinguishing high risk lesions, which has clearly resulted in poor outcomes. This technology has great potential to improve patient outcomes,” said Professor Saman Warnakulasuriya of King’s College London.
The Straticyte™ poster can be viewed here.
“It was important for us to attend the first GOCF. The conference allowed key stakeholders to come together to share issues and learn about innovations and ideas that have the potential to drive oral cancer change globally. I had an opportunity to share the Straticyte™ data and discuss how it can impact patient outcomes by driving early detection,” said Dr. Ralhan. “GOCF’s vision is to reduce oral cancer’s devastating impact and Straticyte™ has a role to play in achieving that goal.”
The inaugural Global Oral Cancer Forum, Challenges in the Global Burden of Oral Cancer: Progress in Early Diagnosis and Prevention, was held in New York City on March 4-5, 2016 with 30+ countries attending. The Forum focused on highlighting the gaps and innovations in prevention, patient care, technology, and services across the oral cancer continuum. Selected clinicians, scientists, epidemiologists, activists, public health experts and others came together to understand how to reduce the global oral cancer burden.
About Proteocyte Diagnostics www.proteocyte.com
Proteocyte Diagnostics is a Canadian company that has developed a novel prognostic oral precancer laboratory service, Straticyte™ that objectively and accurately detects oral lesions at high risk of transforming to cancer and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.